SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ENSC

Ensysce Biosciences, Inc. (NASDAQ:ENSC)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.36+$0.00 (-0.17%)
 
Market cap
$7.00M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 14, 2018
Market Cap$7.00M-78.4%
Revenue (ttm)$5.23M
Net Income-$91.01M-729.4%
EPS-$5.75+9.7%
Shares Out19.46M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume83,390
Open$0.36
Previous Close$0.36
Day's Range$0.36 - $0.37
52-Week Range$0.23 - $1.85
Beta1.09
AnalystsBuy
Price Targetn/a
Earnings DateMar 29, 2027
-0.17% (1D)
No price history available.

About ENSC

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.

Address
7946 Ivanhoe Avenue, La Jolla, CA, 92037, US
Market Cap
7 million
Employees
9
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$444.17K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From ENSC’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-0.17%
5 Days
-10.22%
1 Month
-29.55%
6 Months
+12.99%
1 Year
-78.44%

$ENSC stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ENSC holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ENSC's directors and management

Net Shares Purchased by Insiders−600k−300k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ENSC Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ENSC patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ENSC from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ENSC

VXFVanguard Extended Market ETF$5.41K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ENSC’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
7.19
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Transformational quarter with positive financial results and business highlights outweigh routine conference participation news.

Recent Insider Activity

Buys
2
Sells
0
Buy Value
$444.17K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.